Evidence map›Paper›PMID 24920011›Full record

ArticleBritish journal of anaesthesia2014

Increased μ-opioid receptor expression in metastatic lung cancer.

P A Singleton, T Mirzapoiazova, R Hasina, R Salgia, J Moss

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of anaesthesia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.

  1. A systematic review of the impact of pain on overall survival in patients with cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2016
    Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Opioid System and Epithelial-Mesenchymal Transition.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  16. Review
  17. Review
  18. Review
  19. Anesthesia and cancer recurrence: a narrative review.Anesthesia and pain medicine · 2024
    Review
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

P A SingletonDepartment of Medicine, Section of Pulmonary and Critical Care, Department of Anesthesia and Critical Care and psinglet@medicine.bsd.uchicago.edu.
T MirzapoiazovaDepartment of Medicine, Section of Pulmonary and Critical Care.
R HasinaSection of Hematology/Oncology, Pritzker School of Medicine, The University of Chicago, Chicago, IL 60637, USA.
R SalgiaSection of Hematology/Oncology, Pritzker School of Medicine, The University of Chicago, Chicago, IL 60637, USA.
J MossDepartment of Anesthesia and Critical Care and.
University of Chicago · US

Funding

Re-Engineering Translational Research at the University of ChicagoUL1TR000430 · NCATS · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2012 to 2016
$20.2M
NCATS NIH HHS UL1 TR000430
6 · The paper itself

Abstract

backgroundWe and others have previously demonstrated that the μ-opioid receptor (MOR) is overexpressed in several human malignancies. There is a seven-fold increase in MOR in cell lines of human lung cancer. In animal models, overexpression of MOR promotes tumour growth and metastasis. We, therefore, examined whether MOR expression is increased in metastatic lung cancer.

methodsIn this study, we examined the association between MOR expression and metastasis in archived biopsy samples from patients with lung cancer. Paraffin-embedded patient material was stained using MOR antibody and scored qualitatively by two independent pathologists using a four-point scale.

resultsIn human lung cancer and normal adjacent lung samples obtained from 34 lung cancer patients, MOR expression was increased significantly in cancer samples from patients with lung cancer compared with adjacent control tissue (P=0.0242). When the samples from patients with metastatic lung cancer were separated from the cohort of the total number of patients with lung cancer, we observed an approximately two-fold increase in MOR expression (P=0.0013).

conclusionsThe association between the expression of MOR and the progression of the tumour is consistent with the hypothesis of a direct effect of MOR on cancer progression.

Indexed as

AgedAged, 80 and overBiopsyCarcinoma, Non-Small-Cell LungDisease ProgressionFemaleHumansLung NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm ProteinsNeoplasm StagingReceptors, Opioid, muNeoplasm ProteinsReceptors, Opioid, mulung cancermetastasismethylnaltrexoneMORμ-opioid receptor

Identifiers

PMID24920011
PMCPMC4111280
OpenAlexW2145196793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.